Monoclonal antibody · Antagonist of Interleukin-36 receptor (IL36R) · developed by Vanda Pharmaceuticals
Imsidolimab is a humanized monoclonal antibody that binds the interleukin-36 receptor (IL-36R) and blocks signaling by the pro-inflammatory cytokine IL-36. It is being studied in ulcerative colitis, acne vulgaris and generalized pustular psoriasis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05366855 | Phase 3 | Generalized Pustular Psoriasis | Terminated | VNDA |
| NCT05352893 | Phase 3 | Generalized Pustular Psoriasis | Completed | VNDA |
| NCT04856917 | Phase 2 | Acne Vulgaris | Completed | VNDA |
| NCT04700449 | Phase 2 | Moderate to Severe Ulcerative Colitis | Completed | CNTB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acne VulgarisGeneralized Pustular PsoriasisModerate to Severe Ulcerative Colitis
Updated Nov 8, 2026. Something wrong or missing? Report it on the VNDA page.
See VNDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VNDA catalysts and pipeline →